Physician profile
Peter J Wolff
NPI 1720554884
$1,351.32
in general payments reported to CMS, 2019-2025
11 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.44 · 2022: $51.39 · 2023: $263 · 2024: $610 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,244.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $462.28 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $283.49 | 2022-2025 | Sotyktu |
| Abbvie INC. | $209.24 | 2024-2025 | |
| Dermavant Sciences, INC. | $119.91 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $98.91 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $40.88 | 2025 | Aklief, Nemluvio |
| Regeneron Healthcare Solutions, INC. | $37.14 | 2025 | Dupixent |
| Janssen Biotech, INC. | $35.42 | 2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $24.90 | 2021 | |
| Bioventus LLC | $20.96 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wolff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.